Habib J. Dable

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Noel Donnelly, as attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Habib J. Dable

Form 4 holding Director

Aerovate Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
12,500
Estimated value
$204,625
Report date
05 Jun 2024
Price
$16.37
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tyra Biosciences, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
44,400
Estimated value
Report date
16 Apr 2026
Price
Ownership
Direct
Underlying class
Common
Underlying amount
Form 4 holding Director

PepGen Inc.

Security class
Stock Option (Right to Buy)
Shares / value
34,000
Estimated value
Report date
18 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

SpyGlass Pharma, Inc.

Security class
Stock Option (right to buy)
Shares / value
27,400
Estimated value
Report date
05 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding CEO and President, Director

ACCELERON PHARMA INC

Security class
Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
$29.37
Ownership
Direct
Form 4 holding CEO and President, Director

ACCELERON PHARMA INC

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ALBIREO PHARMA, INC.

Security class
Stock Options (Right to Buy)
Shares / value
0
Estimated value
Report date
02 Mar 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tyra Biosciences, Inc.

Security class
No securities are beneficially owned.
Shares / value
0
Estimated value
Report date
16 Apr 2026
Price
Ownership
Direct

Insider Reports Filed by Habib J. Dable

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .